True, because if success at the pre-clinical stage was a guarantee of success in FDA clinical trials, then share price would be 10 to 20 times higher than it currently is.
Nano is different and the FDA will come to appreciate this eventually. How is it different? It is accurately targeted, something that most drugs are not - they aim a tank at the culprit and hope to wipe it out without too much collateral damage of which there is plenty aka side effects. Nano has no such bull in a china shop syndrome - it hunts down the culprit and eliminates it with NO collateral damage - no side effects - it's a wonderful world with nano.
And NNVC is nano as we all know - The Nano.
So I fully expect our trials to be cautious and observed closely by those with something new to observe but they will be impressed...eventually.
Market Data 
Markets 
AI
